NPB 06Alternative Names: NPB-06
Latest Information Update: 28 Sep 2016
At a glance
- Originator Nihon Pharmaceutical
- Mechanism of Action Blood coagulation factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Venous thrombosis
Most Recent Events
- 29 Sep 2014 Phase-III clinical trials in Venous thrombosis in Japan (IV)